IP Library Granted Patent US 10,093,749
Granted Patent B2
US 10,093,749 · App. 15/023,013 · Granted Oct 9, 2018

Exopolysaccharide produced by lactic acid bacterium

Inventors: Kenji Yamamoto (Otsu, JP); Chiaki Matsuzaki (Kanazawa, JP); Keiko Hisa (Muko, JP)
Assignee: NITTO PHARMACEUTICAL INDUSTRIES, LTD.
C08B37/00A23K20/163A23L29/273A23L33/10A23L33/135A61K8/73A61K31/715A61Q19/00C12P19/04A23V2002/00A23Y2260/35A61K35/74
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,093,749
App. No.
15/023,013
Granted
Oct 9, 2018
Kind
B2
Abstract

Provided are exopolysaccharide produced by novel lactic acid bacteria having an IgA production promoting ability, a production method of the exopolysaccharide, a composition containing the exopolysaccharide, and the like.

Claims (6)

1. A method of stimulating intestinal immunity in a mammal in need thereof, comprising administering to the mammal an effective amount of purified exopolysaccharide produced from Leuconostoc mesenteroides NTM048 strain deposited under accession No. NITE BP-1519, or a mutant strain thereof.

2. A method of treating an allergy in a mammal in need thereof, comprising administering to the mammal an effective amount of purified exopolysaccharide produced from Leuconostoc mesenteroides NTM048 strain deposited under accession No. NITE BP-1519, or a mutant strain thereof.

3. A method of treating an infection of virus in a mammal in need thereof, comprising administering to the mammal an effective amount of purified exopolysaccharide produced from Leuconostoc mesenteroides NTM048 strain deposited under accession No. NITE BP-1519, or a mutant strain thereof.

4. The method of claim 1 , wherein an effective amount of the purified exopolysaccharide produced from Leuconostoc mesenteroides NTM048 strain deposited under accession No, NITE BP-1519 is administered to the mammal.

5. The method of claim 2 , wherein an effective amount of the purified exopolysaccharide produced from Leuconostoc mesenteroides NTM048 strain deposited under accession No, NITE BP-1519 is administered to the mammal.

6. The method of claim 3 , wherein an effective amount of the purified exopolysaccharide produced from Leuconostoc mesenteroides NTM048 strain deposited under accession No, NITE BP-1519 is administered to the mammal.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2021
From: NITTO PHARMACEUTICAL INDUSTRIES, LTD.
To: NOSTER INC.
Reel/Frame 055097/0970 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2016
From: YAMAMOTO, KENJI; MATSUZAKI, CHIAKI; HISA, KEIKO
To: NITTO PHARMACEUTICAL INDUSTRIES, LTD.
Reel/Frame 038033/0539 →
Priority Claims (1)
JP 2013-194656 · Sep 19, 2013 · national
Continuity (1)
Related Publication 20160229925A1 · Aug 11, 2016